Research Analysts Offer Predictions for Catalyst Pharmaceuticals Inc’s Q4 2019 Earnings (CPRX)

Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) – Equities research analysts at Piper Jaffray Companies dropped their Q4 2019 earnings per share estimates for shares of Catalyst Pharmaceuticals in a research note issued on Thursday, November 8th. Piper Jaffray Companies analyst J. Catanzaro now forecasts that the biopharmaceutical company will post earnings of $0.01 per share for the quarter, down from their previous forecast of $0.02. Piper Jaffray Companies has a “Overweight” rating and a $5.00 price objective on the stock. Piper Jaffray Companies also issued estimates for Catalyst Pharmaceuticals’ FY2020 earnings at $0.26 EPS, FY2021 earnings at $0.66 EPS and FY2022 earnings at $1.12 EPS.

Several other research firms have also recently issued reports on CPRX. Cantor Fitzgerald started coverage on shares of Catalyst Pharmaceuticals in a research note on Thursday, September 20th. They issued an “overweight” rating and a $8.00 target price on the stock. BidaskClub upgraded shares of Catalyst Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Thursday, September 27th. Oppenheimer set a $6.00 price objective on shares of Catalyst Pharmaceuticals and gave the company a “buy” rating in a research report on Thursday, August 9th. Zacks Investment Research upgraded shares of Catalyst Pharmaceuticals from a “hold” rating to a “buy” rating and set a $3.25 price objective on the stock in a research report on Monday, August 13th. Finally, HC Wainwright restated a “buy” rating and set a $6.00 price objective on shares of Catalyst Pharmaceuticals in a research report on Thursday, August 9th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and five have assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average price target of $5.71.

NASDAQ CPRX opened at $2.88 on Friday. Catalyst Pharmaceuticals has a 1 year low of $2.18 and a 1 year high of $4.51. The company has a market capitalization of $323.19 million, a price-to-earnings ratio of -13.71 and a beta of 2.05.

Catalyst Pharmaceuticals (NASDAQ:CPRX) last posted its earnings results on Thursday, November 8th. The biopharmaceutical company reported ($0.08) earnings per share (EPS) for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.08).

Institutional investors have recently bought and sold shares of the company. Rhumbline Advisers raised its position in shares of Catalyst Pharmaceuticals by 34.7% during the 2nd quarter. Rhumbline Advisers now owns 90,725 shares of the biopharmaceutical company’s stock valued at $283,000 after buying an additional 23,383 shares in the last quarter. GSA Capital Partners LLP raised its position in shares of Catalyst Pharmaceuticals by 295.7% during the 2nd quarter. GSA Capital Partners LLP now owns 380,605 shares of the biopharmaceutical company’s stock valued at $1,187,000 after buying an additional 284,409 shares in the last quarter. Millennium Management LLC raised its position in shares of Catalyst Pharmaceuticals by 16.5% during the 2nd quarter. Millennium Management LLC now owns 1,610,176 shares of the biopharmaceutical company’s stock valued at $5,024,000 after buying an additional 227,918 shares in the last quarter. Northern Trust Corp raised its position in shares of Catalyst Pharmaceuticals by 22.5% during the 1st quarter. Northern Trust Corp now owns 1,009,947 shares of the biopharmaceutical company’s stock valued at $2,414,000 after buying an additional 185,639 shares in the last quarter. Finally, Lido Advisors LLC raised its position in shares of Catalyst Pharmaceuticals by 46.5% during the 2nd quarter. Lido Advisors LLC now owns 87,506 shares of the biopharmaceutical company’s stock valued at $273,000 after buying an additional 27,766 shares in the last quarter. Hedge funds and other institutional investors own 51.48% of the company’s stock.

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc, a biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases. Its product candidates include Firdapse, a proprietary form of amifampridine phosphate that has completed Phase III clinical trials for the treatment of patients with lambert-eaton myasthenic syndrome; is in Phase III clinical trial to treat congenital myasthenic syndromes; and is in Phase III clinical trial for the treatment of anti-MuSK antibody positive myasthenia gravis, as well as is in Phase II clinical trial for patients with spinal muscular atrophy type 3.

See Also: Cost of Debt

Earnings History and Estimates for Catalyst Pharmaceuticals (NASDAQ:CPRX)

Receive News & Ratings for Catalyst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalyst Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply